Get the Stockscreener App
5.34
0.95%
0.05
After Hours:
5.34
Annexon Inc stock is traded at $5.34, with a volume of 1.02M.
It is up +0.95% in the last 24 hours and down -27.84% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.29
Open:
$5.28
24h Volume:
1.02M
Relative Volume:
0.77
Market Cap:
$563.88M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-2.697
EPS:
-1.98
Net Cash Flow:
$-121.34M
1W Performance:
+3.49%
1M Performance:
-27.84%
6M Performance:
+7.66%
1Y Performance:
+100.75%
1-Day Range:
$5.27
$5.50
1-Week Range:
$5.05
$5.50
52-Week Range:
$2.27
$8.40
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.34 | 563.88M | 0 | -134.24M | -121.34M | -1.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by GSA Capital Partners LLP - Defense World
Trial results for novel CAD treatment now expected early 2025 - Cold Agglutinin News
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - PharmaVoice
Insiders Enjoy US$903k Return After Buying Annexon Stock - Simply Wall St
HC Wainwright Has Negative View of Annexon FY2027 Earnings - MarketBeat
Annexon (NASDAQ:ANNX) Earns “Buy” Rating from HC Wainwright - Defense World
Annexon (NASDAQ:ANNX) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
Financial Contrast: Annexon (NASDAQ:ANNX) & Acasti Pharma (NASDAQ:ACST) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Short Interest Down 12.9% in October - MarketBeat
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Grants 495,000 Stock Options to New Employees in Talent Acquisition Push | ANNX Stock News - StockTitan
Annexon's (ANNX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Annexon's (ANNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Annexon (NASDAQ:ANNX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Logos Global Management LP Adjusts Stake in Annexon Inc - GuruFocus.com
Annexon Biosciences Reports Q3 Financial Results - TipRanks
Annexon Inc (ANNX) Quarterly 10-Q Report - Quartzy
Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones - GlobeNewswire
Annexon Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
FMR LLC's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Creative Planning Has $206,000 Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Analysts Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $15.80 - MarketBeat
JP Morgan Upgrades Annexon (ANNX) - MSN
Annexon shares positive on ARCHER trial data, analyst maintains Buy rating - Investing.com
MacroGenics sells rights to breast cancer drug; Rice’s new biotech accelerator - Endpoints News
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less - The Bakersfield Californian
Annexon Presents Phase 2 Vision Preservation Data with - GlobeNewswire
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely - Yahoo Finance
Tracking Annexon's Progress On Therapies For Complement-mediated Diseases - RTTNews
Annexon EVP Ted Yednock sells $40,073 in stock - Investing.com
Annexon EVP Ted Yednock sells $40,073 in stock By Investing.com - Investing.com South Africa
Insider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells 5,408 Shares of Stock - MarketBeat
Where are the Opportunities in (ANNX) - Stock Traders Daily
A better buy-in window may exist right now for Annexon Inc (ANNX) - SETE News
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting - The Manila Times
Annexon to Present New Phase 2 ARCHER Data for ANX007 in - GlobeNewswire
Annexon Inc (ANNX) stock: A year of ups and downs - US Post News
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Sees Significant Growth in Short Interest - MarketBeat
Eli Lilly and Company (NYSE:LLY) & Annexon (NASDAQ:ANNX) Head to Head Survey - Defense World
A Bullish 2024 Outlook For Annexon Inc (NASDAQ: ANNX) Shares - Stocks Register
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by AQR Capital Management LLC - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Recent Insider Activity Could Benefit Annexon Inc (ANNX) - Knox Daily
Views of Wall Street’s Leading Experts on Annexon Inc - SETE News
Annexon (NASDAQ:ANNX) Shares Up 4.7%What's Next? - MarketBeat
Annexon Inc (NASDAQ: ANNX) Could Fell Another -130.26% - Stocks Register
Is Annexon Inc (ANNX) a opportunity to investors? - US Post News
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):